Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DROSPIRENONE & ETHINYL ESTRADIOL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03A, G03AA) — coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit
  • Ethinyl estradiol + norethindrone (Brevicon): general benefit
  • Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit
  • Drospirenone (Slynd): general benefit
  • Levonorgestrel (Plan B): general benefit

3 more in the class list below

Drospirenone&Ethinyl Estradiol USP 21 · DIN 02421437 · 3.0mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Drospirenone&Ethinyl Estradiol USP 21 · DIN 02421437 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2022-08-31 Health Canada: Marketed since 2021-10-22 · brand DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 21 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Drospirenone&Ethinyl Estradiol USP 21: Formulary list price $6.2181/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.2181 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90606 · Verify on the e-Formulary ↗ (DIN 02421437)

Source record
DIN 02421437: Drospirenone&Ethinyl Estradiol USP 21 Raw flags: sec3=Y Item: 683200107; group id 796; item number 1936; lccId None; manufacturer id GLP Source form: Tab-21 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $6.2181; ministry $6.2181 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421437 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90606
Interchangeable products
Yasmin 21 · DIN 02261723 · $6.2181 Zamine 21 · DIN 02410788 · $6.2181
Shortage status: resolved shortage (ended 2025-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421437
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Yasmin 21 · DIN 02261723 · 3.0mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Yasmin 21 · DIN 02261723 Manufacturer: Bayer Inc., Health Care Division; listing date 2007-06-06 Health Canada: Marketed since 2007-12-13 · brand YASMIN 21 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $6.2181 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74710 · Verify on the e-Formulary ↗ (DIN 02261723)

Source record
DIN 02261723: Yasmin 21 Raw flags: sec3=Y Item: 683200107; group id 796; item number 1936; lccId None; manufacturer id BAH Source form: Tab-21 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $12.6900; ministry $6.2181 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261723 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74710
Interchangeable products
Drospirenone&Ethinyl Estradiol USP 21 · DIN 02421437 · $6.2181 Zamine 21 · DIN 02410788 · $6.2181
Shortage status: resolved shortage (ended 2022-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261723
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zamine 21 · DIN 02410788 · 3.0mg & 0.03mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Zamine 21 · DIN 02410788 Manufacturer: Apotex Inc.; listing date 2013-10-31 Health Canada: Marketed since 2020-09-01 · brand ZAMINE 21 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Zamine 21: Formulary list price $6.2181/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.2181 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89544 · Verify on the e-Formulary ↗ (DIN 02410788)

Source record
DIN 02410788: Zamine 21 Raw flags: sec3=Y Item: 683200107; group id 796; item number 1936; lccId None; manufacturer id APX Source form: Tab-21 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $6.2181; ministry $6.2181 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410788 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89544
Interchangeable products
Drospirenone&Ethinyl Estradiol USP 21 · DIN 02421437 · $6.2181 Yasmin 21 · DIN 02261723 · $6.2181
Shortage status: resolved shortage (ended 2024-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410788
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Drospirenone&Ethinyl Estradiol USP · DIN 02462060 · 3.0mg & 0.02mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Drospirenone&Ethinyl Estradiol USP · DIN 02462060 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2022-09-29 Health Canada: Marketed since 2021-09-07 · brand DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.02 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Drospirenone&Ethinyl Estradiol USP: Formulary list price $8.2600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.2600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94980 · Verify on the e-Formulary ↗ (DIN 02462060)

Source record
DIN 02462060: Drospirenone&Ethinyl Estradiol USP Raw flags: sec3=Y Item: 683200111; group id 796; item number 1937; lccId None; manufacturer id GLP Source form: Tab-28 Pk; strength: 3.0mg & 0.02mg Recorded listing: General benefit Source prices (unrounded): $8.2600; ministry $8.2600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462060 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94980
Interchangeable products
MYA · DIN 02415380 · $8.2600 Yaz · DIN 02321157 · $8.2600
Shortage status: resolved shortage (ended 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462060
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Drospirenone&Ethinyl Estradiol USP 28 · DIN 02421445 · 3.0mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Drospirenone&Ethinyl Estradiol USP 28 · DIN 02421445 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2022-08-31 Health Canada: Marketed since 2021-10-22 · brand DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP 28 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Drospirenone&Ethinyl Estradiol USP 28: Formulary list price $6.2188/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.2188 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90607 · Verify on the e-Formulary ↗ (DIN 02421445)

Source record
DIN 02421445: Drospirenone&Ethinyl Estradiol USP 28 Raw flags: sec3=Y Item: 683200108; group id 796; item number 1938; lccId None; manufacturer id GLP Source form: Tab-28 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $6.2188; ministry $6.2188 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02421445 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90607
Interchangeable products
Yasmin 28 · DIN 02261731 · $6.2188 Zamine 28 · DIN 02410796 · $6.2188
Shortage status: active shortage (reported 2026-04-16, last updated 2026-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421445
Shortage record checked 2026-09-13T08:10:21.292534+00:00

MYA · DIN 02415380 · 3.0mg & 0.02mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
MYA · DIN 02415380 Manufacturer: Apotex Inc.; listing date 2014-08-28 Health Canada: Marketed since 2020-09-01 · brand MYA · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3.00 MG, ETHINYL ESTRADIOL 0.02 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

MYA: Formulary list price $8.2600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $8.2600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89999 · Verify on the e-Formulary ↗ (DIN 02415380)

Source record
DIN 02415380: MYA Raw flags: sec3=Y Item: 683200111; group id 796; item number 1937; lccId None; manufacturer id APX Source form: Tab-28 Pk; strength: 3.0mg & 0.02mg Recorded listing: General benefit Source prices (unrounded): $8.2600; ministry $8.2600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415380 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89999
Interchangeable products
Drospirenone&Ethinyl Estradiol USP · DIN 02462060 · $8.2600 Yaz · DIN 02321157 · $8.2600
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-02, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415380
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Yasmin 28 · DIN 02261731 · 3.0mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Yasmin 28 · DIN 02261731 Manufacturer: Bayer Inc., Health Care Division; listing date 2007-06-06 Health Canada: Marketed since 2007-11-28 · brand YASMIN 28 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $6.2188 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74711 · Verify on the e-Formulary ↗ (DIN 02261731)

Source record
DIN 02261731: Yasmin 28 Raw flags: sec3=Y Item: 683200108; group id 796; item number 1938; lccId None; manufacturer id BAH Source form: Tab-28 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $12.6900; ministry $6.2188 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261731 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74711
Interchangeable products
Drospirenone&Ethinyl Estradiol USP 28 · DIN 02421445 · $6.2188 Zamine 28 · DIN 02410796 · $6.2188
Shortage status: resolved shortage (ended 2026-03-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261731
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Yaz · DIN 02321157 · 3.0mg & 0.02mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Yaz · DIN 02321157 Manufacturer: Bayer Inc., Health Care Division; listing date 2009-09-30 Health Canada: Marketed since 2009-01-06 · brand YAZ · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.02 MG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $8.2600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656 · Verify on the e-Formulary ↗ (DIN 02321157)

Source record
DIN 02321157: Yaz Raw flags: sec3=Y Item: 683200111; group id 796; item number 1937; lccId None; manufacturer id BAH Source form: Tab-28 Pk; strength: 3.0mg & 0.02mg Recorded listing: General benefit Source prices (unrounded): $16.8500; ministry $8.2600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656
Interchangeable products
Drospirenone&Ethinyl Estradiol USP · DIN 02462060 · $8.2600 MYA · DIN 02415380 · $8.2600
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02321157
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zamine 28 · DIN 02410796 · 3.0mg & 0.03mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Zamine 28 · DIN 02410796 Manufacturer: Apotex Inc.; listing date 2013-10-31 Health Canada: Marketed since 2020-09-01 · brand ZAMINE 28 · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.03 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Zamine 28: Formulary list price $6.2188/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.2188 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89545 · Verify on the e-Formulary ↗ (DIN 02410796)

Source record
DIN 02410796: Zamine 28 Raw flags: sec3=Y Item: 683200108; group id 796; item number 1938; lccId None; manufacturer id APX Source form: Tab-28 Pk; strength: 3.0mg & 0.03mg Recorded listing: General benefit Source prices (unrounded): $6.2188; ministry $6.2188 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89545
Interchangeable products
Drospirenone&Ethinyl Estradiol USP 28 · DIN 02421445 · $6.2188 Yasmin 28 · DIN 02261731 · $6.2188
Shortage status: resolved shortage (ended 2026-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410796
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL DESOGESTREL & ETHINYL ESTRADIOL · General benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077799.PDF; date NOV 20, 2024; DIN 02042479; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & ETONOGESTREL · Off-Formulary Interchangeable, not an ODB benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077755.PDF; date DEC 12, 2004; DIN 02253186; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & LEVONORGESTREL · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) 1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. PM: https://pdf.hres.ca/dpd_pm/00081001.PDF; date 2025-07-07; DIN 00707503; fetched 2026-09-10 Product monograph NORETHINDRONE · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. PM: https://pdf.hres.ca/dpd_pm/00085300.PDF; date JUL 10, 2026; DIN 02410303; fetched 2026-09-10 Product monograph NORGESTIMATE & ETHINYL ESTRADIOL · Listed, not a benefit (4), General benefit (6) Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081457.PDF; date 2025-08-21; DIN 02401967; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications YASMIN (drospirenone and ethinyl estradiol tablet) is indicated for: • Conception Control • Treatment of moderate acne vulgaris in women ≥16 years of age who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche 1.1 Pediatrics Pediatrics (˂16 years of age): The safety and efficacy of YASMIN has not been established in women under the age of 16 years. Use of this product before menarche is not indicated (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: YASMIN is not indicated for use in postmenopausal women. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00080997.PDF PM date: 2025-07-07 Source product: YASMIN 21; DIN 02261723; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Drospirenone&Ethinyl Estradiol USP 28 · DIN 02421445 Shortage status: active shortage (reported 2026-04-16, last updated 2026-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02421445

Check this DIN again

MYA · DIN 02415380 Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-02, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415380

Check this DIN again